-
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
•
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for EVM14, a tumor-associated antigen (TAA) vaccine, has been cleared by the US Food and Drug Administration (FDA). This milestone marks a significant advancement for the company’s innovative oncology pipeline. EVM14’s Mechanism and Pre-Clinical SuccessEVM14 is…
-
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
•
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform…
-
CSPC Pharmaceutical Group Gains NMPA Approval for SYS6040 Clinical Trial
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its investigational antibody-drug conjugate (ADC) SYS6040. The trial will focus on evaluating the safety and efficacy of SYS6040 in patients with advanced solid tumors. Promising Pre-Clinical…
-
Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
•
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully passed the Hong Kong Stock Exchange (HKEX) listing hearing and disclosed its post-hearing information on March 23. Morgan Stanley, Jefferies, and CITIC Securities Company Limited are serving as joint sponsors for the IPO. Pipeline and…
-
China Biopharmaceutical Leads AI Integration with DeepSeek-R1
•
Since the beginning of the year, China’s self-developed AI assistant DeepSeek has made a significant splash in the global AI sector, sparking a digital revolution. Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has been at the forefront of integrating AI into its core strategy. The company…
-
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced the launch of the Invenia Automated Breast Ultrasound (ABUS) Premium. This advanced 3D ultrasound system integrates artificial intelligence (AI) and innovative features to enable faster, reproducible supplemental screening and streamline exam readings for patients with…
-
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
•
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan. The drug is approved for treating adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer who have undergone prior chemotherapy. First TROP2-Directed Therapy…
-
Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist in advanced therapy medicinal products (ATMPs), has formed a partnership with US-based biotech firm Eureka Therapeutics, Inc. The collaboration focuses on the global clinical development of T-cell therapies, with financial details remaining undisclosed. Eureka Therapeutics’…
-
Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
•
China-based Triastek Inc., a pharmaceutical-focused 3D printing company, has announced receiving clinical approval in the US for its T20G. This 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) was previously cleared for trials in China in January of last year. T20G’s Technological AdvantagesT20G leverages Triastek’s patented 3D Microstructure for Gastric Retention…
-
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
•
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the US Food and Drug Administration (FDA) to market its Tremfya (guselkumab) as a treatment for moderately to severely active Crohn’s disease (CD). This IL-23 inhibitor now offers both subcutaneous (SC) and intravenous (IV) induction options…
-
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools. Understanding BPDCNBPDCN is an aggressive orphan hematologic malignancy with…
-
Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
•
US-based Elevation Oncology, Inc. (NASDAQ: ELEV) has announced the decision to terminate development of EO-3021 following disappointing Phase 1 data, which caused its stock price to plummet 41% before trading. EO-3021’s Background and Licensing DealEO-3021, a Claudin 18.2-targeted antibody drug conjugate (ADC) originated by China’s CSPC Pharmaceutical Group Ltd (HKG:…
-
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
•
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt Biotech Corp. receiving approval to initiate a clinical study for its GenSci120 in rheumatoid arthritis (RA) in the United States. This marks a significant step forward in the development of this innovative biologic product for…
-
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
•
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the US Food and Drug Administration (FDA) for the treatment of adults with C3 glomerulopathy (C3G). This marks the first and only approved therapy specifically targeting this rare kidney disease, which is characterized by a poor…
-
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB 28.9 billion (USD 4 billion), marking a 10.2% year-on-year increase. This growth was driven by strong performances across multiple therapeutic areas and the continued expansion of innovative drug sales. Revenue BreakdownInnovative drugs generated RMB 12…
-
Arcutis Biotherapeutics’ Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its US partner Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) has filed a supplementary New Drug Application (sNDA) for Zoryve cream (roflumilast) 0.05% with the US Food and Drug Administration (FDA). The application seeks approval for the topical use of Zoryve in children…
-
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
•
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager (MCE) targeting CD20, through the acquisition of its developer, Dren Bio, Inc. The deal underscores Sanofi’s commitment to expanding its portfolio in autoimmune diseases with a novel therapeutic approach. Deal StructureSanofi will pay an upfront…
-
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
•
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot firm Hinova Pharmaceuticals Inc. (SHA: 688302) to jointly explore and develop overseas markets for their collaborative products. Collaboration DetailsThe partnership between Kexing Biopharm and Hinova Pharmaceuticals is designed to leverage their combined strengths in oncology…
-
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase III study for its KX-826 (pyrilutamide) in alopecia. The trial met the primary endpoint with statistical significance and demonstrated the drug’s outstanding safety and efficacy. Clinical Trial ResultsAt week 52, patients showed significant improvements in…
-
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the National Medical Products Administration (NMPA) to initiate clinical trials for its JS212, a bispecific antibody drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). This marks a…
